United States Health

Corteva (NYSE:CTVA), the agricultural technology giant, and Hexagon Bio, a biotechnology company focused on nature-derived therapeutics, announced a multi-million-dollar joint venture aimed at accelerating the discovery of new crop protection solutions.

Cosette Pharmaceuticals said the U.S. Food and Drug Administration has approved its abbreviated new drug application for the first generic version of CIPRO HC, granting the company 180 days of Competitive Generic Therapy exclusivity and ending a more than 27-year stretch without a generic alternative.

Royalty Pharma (NASDAQ:RPRX) said it has acquired a royalty interest in two of Nuvalent’s lead cancer programs for as much as $315 million, adding long-dated exposure to a pair of next-generation tyrosine kinase inhibitors targeting ALK- and ROS1-altered non-small cell lung cancer.

Palvella Therapeutics (NASDAQ:PVLA) said the U.S. Food and Drug Administration has granted Fast Track Designation to QTORIN 3.9% rapamycin anhydrous gel for treating angiokeratomas, a dermatologic condition with no currently approved therapies.

Nektar Therapeutics (NASDAQ:NKTR) reported mixed Phase 2b results for rezpegaldesleukin in severe-to-very-severe alopecia areata, showing meaningful clinical activity but narrowly missing the trial’s primary endpoint in the modified intent-to-treat population.

Organigram Global (NASDAQ:OGI), Canada’s leading recreational cannabis producer, reported record fourth-quarter and full-year results for the period ended September 30, 2025.

Bicycle Therapeutics (NASDAQ:BCYC), developer of a novel class of bicyclic peptide-based medicines, has secured a 15-year contract with the UK Nuclear Decommissioning Authority granting access to up to 400 tonnes of reprocessed uranium (RepU)—a resource the company says will underpin long-term production of lead-212 (212Pb) for its emerging cancer radioconjugate programs.

Organogenesis (NASDAQ:ORGO) has secured FDA confirmation to initiate a rolling Biologics License Application for ReNu, its knee osteoarthritis treatment, with submission set to begin before year-end 2025.

Aldeyra Therapeutics (NASDAQ:ALDX) said the U.S. Food and Drug Administration has extended the PDUFA target action date for its reproxalap New Drug Application (NDA) for dry eye disease to March 16, 2026, adding roughly three months to the original timeline.

Palvella’s (NASDAQ:PVLA) topical rapamycin gel improved lesions in most patients and showed a favorable safety profile, supporting upcoming FDA discussions on Breakthrough designation and Phase 3 development.

Greenwich LifeSciences (NASDAQ:GLSI) announced an approximately 80% reduction in recurrence rates from a preliminary analysis of the 250-patient open-label arm of its Phase 3 FLAMINGO-01 breast cancer immunotherapy trial, GLSI-100.